Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors

Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors

The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regar...

Full description

Bibliographic Details
Main Authors: Samra Turajlic, Igor Puzanov, Paul C Lorigan, Benjamin Switzer
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/7/e002835.full
id doaj-6cf348571459444c958d6348f9940c7d
record_format Article
spelling doaj-6cf348571459444c958d6348f9940c7d2021-08-04T16:30:44ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-07-019710.1136/jitc-2021-002835Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitorsSamra Turajlic0Igor Puzanov1Paul C Lorigan2Benjamin Switzer3Renal and Skin Units, Royal Marsden NHS Foundation Trust, London, UKDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USADivision of Cancer Sciences, The University of Manchester, Manchester, UKDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USAThe clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regarding the use of immune checkpoint inhibitors (ICIs) in patients with cancer during the SARS-CoV-2 pandemic, with a focus on patients with melanoma and renal cell carcinoma (RCC). More specifically, we summarize the theoretical concepts and available objective data regarding the relationships between ICIs and the antiviral immune response, along with recommended clinical approaches to the management of melanoma and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic. Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 vaccines and broader implications toward future pandemics are also discussed.https://jitc.bmj.com/content/9/7/e002835.full
collection DOAJ
language English
format Article
sources DOAJ
author Samra Turajlic
Igor Puzanov
Paul C Lorigan
Benjamin Switzer
spellingShingle Samra Turajlic
Igor Puzanov
Paul C Lorigan
Benjamin Switzer
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer
author_facet Samra Turajlic
Igor Puzanov
Paul C Lorigan
Benjamin Switzer
author_sort Samra Turajlic
title Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
title_short Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
title_full Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
title_fullStr Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
title_full_unstemmed Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
title_sort clinical and immunologic implications of covid-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2021-07-01
description The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regarding the use of immune checkpoint inhibitors (ICIs) in patients with cancer during the SARS-CoV-2 pandemic, with a focus on patients with melanoma and renal cell carcinoma (RCC). More specifically, we summarize the theoretical concepts and available objective data regarding the relationships between ICIs and the antiviral immune response, along with recommended clinical approaches to the management of melanoma and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic. Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 vaccines and broader implications toward future pandemics are also discussed.
url https://jitc.bmj.com/content/9/7/e002835.full
work_keys_str_mv AT samraturajlic clinicalandimmunologicimplicationsofcovid19inpatientswithmelanomaandrenalcellcarcinomareceivingimmunecheckpointinhibitors
AT igorpuzanov clinicalandimmunologicimplicationsofcovid19inpatientswithmelanomaandrenalcellcarcinomareceivingimmunecheckpointinhibitors
AT paulclorigan clinicalandimmunologicimplicationsofcovid19inpatientswithmelanomaandrenalcellcarcinomareceivingimmunecheckpointinhibitors
AT benjaminswitzer clinicalandimmunologicimplicationsofcovid19inpatientswithmelanomaandrenalcellcarcinomareceivingimmunecheckpointinhibitors
_version_ 1721222182380503040

Similar Items